ONC — BeOne Medicines Ltd.

Summary of BeOne Medicines Q4 and Full Year 2025 Earnings Call

1. Key Financial Results and Metrics

• Q4 2025 Product Revenue: $1.5 billion, a 32% year-over-year increase.
• BRUKINSA Global Revenues: $1.1 billion in Q4, a 38% increase; full-year revenues reached $3.9 billion, up 49%.
• U.S. Sales: $845 million in Q4, driven by a 30% volume growth.
• Gross Margin: Improved to 87% from 84% in the previous year.
• Operating Income: $447 million, marking a profitable year.
• Net Income: $287 million, with GAAP diluted earnings per ADS of $2.53; non-GAAP net income was $918 million, translating to $8.09 per ADS.
• Free Cash Flow: $380 million in Q4, totaling over $940 million for the year.

2. Strategic Updates and Business Highlights

• BRUKINSA: Positioned as the leading BTK inhibitor globally, with superior efficacy and safety compared to competitors like ibrutinib and acalabrutinib.
• Pipeline Progress: Significant advancements in R&D, including the approval of sonrotoclax for relapsed/refractory MCL and CLL, and ongoing Phase III studies for multiple assets.
• Innovation Goals: BeOne aims to establish a cure for CLL and develop fixed-duration therapies that outperform current options.
• Market Expansion: Continued growth in China and other international markets, with a focus on capturing more share in the fixed-duration treatment segment.

3. Forward Guidance and Outlook

• 2026 Revenue Projection: Expected between $6.2 billion to $6.4 billion, driven by continued growth of BRUKINSA and initial contributions from new launches like sonrotoclax and zanidatamab.
• Operating Expenses: Anticipated to be between $4.7 billion and $4.9 billion, reflecting ongoing investments in commercial growth and pipeline advancement.
• Tax Considerations: Potential recognition of deferred tax assets could provide a material tax benefit in 2026.

4. Bad News, Challenges, or Points of Concern

• Competitive Pressures: Concerns regarding the entry of competitor products into the market, particularly those subject to CMS drug price negotiations.
• Fixed-Duration Therapy Risks: Current fixed-duration therapies (e.g., venetoclax) show inferior efficacy and safety profiles compared to continuous BTK inhibitors, which may hinder their adoption.
• Market Dynamics: The challenge of converting patients from existing therapies to new treatments, especially in the competitive landscape of CLL therapies.

5. Notable Q&A Insights

• Pricing Dynamics: Management emphasized the differentiated value of BRUKINSA, asserting confidence in its market position despite competitive pressures.
• Market Share Strategy: The company aims to capture the fixed-duration treatment segment, which currently represents about 50% of the patient population, without sacrificing revenues from continuous therapies.
• Immunology Pipeline: BeOne is exploring opportunities in immunology, with plans to identify cornerstone therapies in the next 2-3 years.
• BTK Degrader Development: Ongoing Phase III studies are crucial for establishing the BTK degrader's role in treatment, with management optimistic about its potential impact.

Overall, BeOne Medicines demonstrated strong financial performance in 2025, with a focus on innovation and market leadership in CLL therapies, while navigating competitive challenges and expanding its pipeline.